StaphVax

decreases rate of nosocomial infections by boosting immunity against Staphylococcus aureus

Networked: 3 relevant articles (0 outcomes, 3 trials/studies)

1.	Chronic Kidney Failure (Chronic Renal Failure) 01/01/2003 - "Nabi-StaphVAX completed a multicentre, phase III trial in the US involving 1800 end-stage renal disease patients on haemodialysis. " 01/01/2002 - "Nabi met with the FDA in December 2000 to review results from its phase III trial of StaphVAX in patients with ESRD. " 01/01/2002 - "In February 2001, Nabi revealed that it was movingforward during the second quarter of 2001 with previously stated plans to conduct a boosting study of StaphVAX in patients with end-stage renal disease (ESRD). "
2.	Infections 01/01/2006 - "Vaccination against Staphylococcus aureus with StaphVAX induced specific antibodies potentially preventing bacteraemia; however, there are no studies on efficacy in the prophylaxis of device-associated infections with this vaccine." 01/01/2002 - "StaphVAX is a bivalent polysaccharide- and protein-conjugated vaccine, directed against capsular Staphylococcus aureus types 5 and 8, which are associated with 80 to 90% of S aureus clinical infections. "